Moderate-vigorous Intermittent Physical Activity (M-VILPA) in Stroke
Launched by UNIVERSITAT INTERNACIONAL DE CATALUNYA · Sep 13, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a specific type of physical activity called Moderate-vigorous Intermittent Physical Activity (M-VILPA) on people who have had a stroke. The goal is to see how this type of exercise can help stroke survivors who are living in the community and are in the late recovery phase after their hospital stay. Regular physical activity is important for improving strength, balance, and overall health, but many stroke survivors tend to become less active after leaving the hospital. By encouraging these individuals to participate in M-VILPA, researchers hope to help them maintain their physical abilities and reduce the risk of further health issues.
To be eligible for this trial, participants must be adults aged 57 and older who have had a stroke confirmed by a doctor and have been discharged from the hospital. They should also be able to move independently. Unfortunately, those with other serious neurological conditions or severe leg injuries cannot participate. If selected, participants can expect to engage in guided physical activities designed to improve their health and well-being. This study is not yet recruiting, but it aims to provide valuable insights into how exercise can benefit stroke survivors in their daily lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adults aged ≥57 in the late subacute phase post-stroke.
- • who live in the community
- • whose clinician confirmed a diagnosis of stroke (ischaemic/haemorrhagic)
- • discharged from hospital inpatient regimen
- • with independent mobility skills (Barthel Index ≥ 40 points).
- Exclusion Criteria:
- • • other neurological diseases (e.g. Parkinson disease) or severe lower limb injuries.
About Universitat Internacional De Catalunya
The Universitat Internacional de Catalunya (UIC) is a prestigious higher education institution situated in Barcelona, Spain, renowned for its commitment to academic excellence and innovation in research. With a strong emphasis on interdisciplinary collaboration, UIC actively engages in clinical trials that aim to advance medical knowledge and improve patient outcomes. The university's dedicated research teams are equipped with cutting-edge facilities and experienced professionals, enabling them to conduct rigorous studies across various health-related fields. UIC's focus on ethical practices and compliance ensures that all clinical trials are conducted with the highest standards of scientific integrity and participant safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Rosa Cabanas-Valdés, PhD
Principal Investigator
Universitat Internacional de Catalunya
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported